

Figure S3. Bioactivity of encapsulated 4-AP within the (4-AP)-PLGA carriers applied day 3 post injury. (A) Released 4-AP from (4-AP)-PLGA particles was collected and quantified, and then 50 μ g was administered to mice with sciatic nerve crush injuries at 5 days post-injury to test the bioactivity of encapsulated 4-AP. Significant SFI improvement was observed after 4-AP administration. (B) Released 4-AP from (4-AP)-PLGA films was collected and quantified, and then 50 μ g was administered to mice with sciatic nerve crush injuries quantified to test the bioactivity of the encapsulated 4-AP. Significant SFI improvement was observed immediately (animals were assessed 15 minutes after administration of 4AP for this experiment). (* i : p <0.05; two-tailed unpaired t-test; N=3 for each group)

